Brian Taylor Slingsby
Known title: DirectorCIK: 0001963901
Brian Taylor Slingsby's purchase track record
Brian Taylor Slingsby has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/13/2025 | MLYS | $3.50M | +10.5% | +175.3% | +19.3% |
| 2/14/2023 | MLYS | $4.00M | -14.2% | -30.8% | +7.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MLYS | ▼ Sell | Open Market | 104,320 | $3.0M | 9/22/2026 | View on chart |
| MLYS | ▲ Buy | Grant | 6,200 | $0 | 2/19/2026 | View on chart |
| MLYS | ▼ Sell | Other | 6,200 | $0 | 2/19/2026 | View on chart |
| MLYS | ▼ Sell | Other | 6,200 | $0 | 2/19/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 1,000,000 | $43.4M | 11/20/2025 | View on chart |
| MLYS | ▲ Buy | Open Market | 259,259 | $3.5M | 3/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 550,000 | $7.2M | 7/24/2024 | View on chart |
| MLYS | ▼ Sell | Other | 4,314,093 | — | 2/14/2023 | View on chart |
| MLYS | ▲ Buy | Open Market | 250,000 | $4.0M | 2/14/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.